TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Knowledge and beliefs regarding gout management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reported treatment practices of primary care physicians
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound Measurement of Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in frequency of condomless sex
Endpoint domain: Adverse events/effects
Primary endpoint: Number of incident STIs from Baseline
Endpoint domain: Adverse events/effects
Primary endpoint: adenosine-induced coronary flow reserve (CFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline to Week 4 in the General Subscale of the MFSI-SF
Endpoint domain: Life impact
Endpoint subdomain: General outcomes
Primary endpoint: Poor outcome
Endpoint domain: Mortality/survival
Primary endpoint: Skin biopsy results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Per Facility With Hemoglobin < 10 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Per Facility With Hemoglobin > 12 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Per Facility With Urea Reduction Ratio (URR) ≥ 65%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of specific clinical criteria leading to delivery complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Physical Activity Levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Who Met the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Met the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Met the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Postdose
Endpoint domain: Adverse events/effects
Primary endpoint: Change in renal functional reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: demand/delivery ratio for MO and rescue drug
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Tolerated Dose (MTD) of docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response against poliovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dengue IgM concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NS1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC0-72 of linagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of linagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-infinity of pioglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of pioglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short attention test (BTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trail Making Test (TMT A-B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Test of Colors and Words (Stroop Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symbol and digit test (SDMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PASAT test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bells Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: European Quality of Life-5 Dimension 3 Level (EQ-5D) index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Random blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cambridge neuropsychological test automated battery (CANTAB)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of serious and significant adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: clinical outcome at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Standard Drinking Units Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal knowledge on FAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Likelihood to drink alcohol
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Progression-free Survival at 6 Months (PFS6)
Endpoint domain: Mortality/survival
Primary endpoint: Patient monthly health care cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in regional brain BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Global Impression of Severity of Suicidality (Revised)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression of Imminent Suicide Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression of Long Term Suicide Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between continuous glucose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients chronically relieved from mitral valve insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of mitral valve regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Target Vessel Failure (TVF) - Cardiac Death
Endpoint domain: Mortality/survival
Primary endpoint: Target Vessel Failure (TVF) - Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Target Vessel Failure (TVF) - Revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Migraine incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: In-hospital Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Duration of chemotherapy induced neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients whose disease has not progressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[0 to Tau]) of Dolutegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Dolutegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration at the End of the Dosing Interval (Ctau) of Dolutegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in non-inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Positive Reactions to Nickel Sulfate
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Reactions to Neomycin Sulfate
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Reactions to Wool Alcohol
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Reactions to Potassium Dichromate
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Reactions to Caine Mix
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Reactions to Fragrance Mix
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Box and Blocks test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose limited toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Urgency Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain in rest in the op-area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 28 PCR corrected cure rates
Endpoint domain: Mortality/survival
Primary endpoint: Number of methamphetamine-positive urine tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient self-reported anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Azithromycin trough levels in amniotic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Nasal Mucosal Seroconversion (Immunoglobulin A [IgA])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient-Reported Outcomes Measurement Information Systems (PROMIS) Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinalyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breathalyzer tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report of drug or alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Leukocyte expression of the C-FOS and DUSP1 genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Force on the elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower urinary tract symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: postoperative cognitive change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: cortisol concentrations changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean change in joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in LMS27 scale for upper limb lymphoedema
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in LYMQOL-LEG scale for lower limb lymphoedema
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in residents' quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NNN urinary concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titer of VZV Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment-emergent or Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of Levomethadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative/antioxidative stress markers (malondialdehyde [MDA])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxidative/antioxidative stress markers (catalase [CAT])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxidative/antioxidative stress markers (superoxide dismutase [SOD])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Body Weight (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily peak-flow variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in asthma control questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in levels of ß thromboglobulin (ß TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite Efficacy Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedural success of ERCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and feasibility of immunization
Endpoint domain: Adverse events/effects
Primary endpoint: Peritonitis Rate of Stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subtle musculoskeletal signs of Pompe disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pompe-specific clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevation in Pompe-specific biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Walking Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of side branch ostial compromise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Age-Equivalent scores of the Vineland Adaptive Behavior Scales
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of subjects who become seizure-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall percent of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of treatment methods of HFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite measure of Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RSA migration in 3 dimensions of the acetabular components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ΔIFN-ß gene and/or protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ΔIFN-λ gene and/or protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ΔViral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: First fixation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in tumor dimensions of target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reproducibility of Qaw measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doubling Concentration of Methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weighted Mean Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum MMP7 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial expression of HLA-DQ in muscle biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endothelial expression of interleukin-1 alpha in muscle biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Carotid artery intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Established Maximum Tolerated Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal perception of breastfeeding efficiency at hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maternal perception of milk supply at hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motor Behavior Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate During the First Course of JZP-458 Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Achievement of 20% reduction in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival (no additional intervention)
Endpoint domain: Mortality/survival
Primary endpoint: Dependency level
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Feasibility of the guide
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the guide
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Iron content in human bone samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arterial stiffness (pulse wave velocity and augmentation index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of overall DVT events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: 100-day transplant-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: 24-month HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in insulin sensitivity (Si)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose based on incidence of DLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with an objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enhanced visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enhanced field of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower threshold for electrical evoked phosphenes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody levels against the MERS-CoV glycoprotein S
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Liver fibrosis grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of cervical lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall pain during the previous 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Index of ankylosing spondylitis of Dougados
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall assessment of disease activity by the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Disorder Examination-Questionnaire (EDE-Q) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incisional drainage, swelling or gaps of incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of isthmocele
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of residual myometrial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS Change at 60 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vulnerable plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Residual Cancer Burden (RCB) 0-I index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success rate of corneal reepithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal adherence to zidovudine syrup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Failure-free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated Dilation of the Brachial Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ASAS Response at 20% level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fuster-BEWAT Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast feeding self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent decrease from baseline in integrated gastric acidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Diabetes Self-Management Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of metaphase II oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change From Baseline in Mean Pain Box Scale-11 Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue